Evaxion Biotech A/S
EVAX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.06 | 0.10 | -0.12 |
| FCF Yield | -285.13% | -75.89% | -49.70% | -21.63% |
| EV / EBITDA | -0.98 | -1.34 | -2.19 | -3.27 |
| Quality | ||||
| ROIC | -159.60% | -340.73% | -130.73% | -70.69% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.22 | 0.80 | 1.11 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 27.21% | 31.80% | -11.90% | -81.54% |
| Safety | ||||
| Net Debt / EBITDA | -0.52 | -0.25 | 0.13 | 1.18 |
| Interest Coverage | -15.31 | -24.75 | -16.75 | -28.23 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 202.80 | 0.00 | 0.00 | 0.00 |